baber/WOPTO huggingface dataset:
Patent NZ-256151-A (NZ)
Title: Flippable pixel display element
Inventor: HOGBERG BO
IPC: G09F9/37
Filed: 1993-09-21
Abstract: PCT No. PCT/SE93/00763 Sec. 371 Date Feb. 16, 1995 Sec. 102(e) Date Feb. 16, 1995 PCT Filed Sep. 21, 1993 PCT Pub. No. WO94/07231 PCT Pub. Date Mar. 31, 1994A display element is adapted to be arranged together with other similar elements in rows and columns for displaying signs and comprises a housing (2), a surface element (6) connected to said housing and movable between two positions for displaying different surface information (4,5), as well as a coil (9) optionally magnetizable in opposite directions, connected to the housing and adapted to actuate the surface element to occupy one or the other of said positions depending upon the direction of said magnetizing. The display element is adapted to be selected to magnetize the coil thereof by activating the column or row to which it belongs through lines interconnecting all display elements arranged in a column and a row, respectively. Means (18,19) are integrated with the housing (2) and arranged to block magnetizing of the coil of the display element on activation of an interconnecting line (15 and 16,17, respectively) belonging to the row of the element as mentioned if the interconnecting lines (16,17 and 15, respectively) belonging to the column of this element are at the same time unactivated and conversely.
Patent NZ-281421-A (NZ)
Title: Interleukin-3 variant or mutant fusion protein
Inventor: BAUER CHRISTOPHER S
IPC: C12N15/09
Filed: 1995-02-02
Abstract: A claimed fusion protein has the formula: R1-L-R2, R2-L-R1, R1-R2, R2-R1, R1-L-R1, or R1-R1 where R1 is a human interleukin-3 (IL-3) mutant of a given formula and may have Met- or Met-Ala- preceding amino acid 1, and opt. where 1-14 amino acids can be deleted from the N-terminus and/or 1-15 amino acids can be deleted from the C-terminus, and where 4-44, 4-35 or 4-26 amino acids termed 'Xaa" are different from the corresp. amino acids of native (1-133) human IL-3; R2 is an IL-3, IL-3 variant or a colony-stimulating factor; and L is a linker capable of binding R1 to R2. Various sequences are given for R1. Also claimed is recombinant DNA comprising vector DNA and DNA encoding a fusion protein polypeptide (42 nucleotide sequences given).
Patent NZ-294177-A (NZ)
Title: 1-aralkyl-, 2-aryl-substituted naphthyl derivatives and pharmaceutical formulations
Inventor: BRYANT HENRY UHLMAN
IPC: A61K31/135
Filed: 1995-09-18
Abstract: The present invention provides a compound of formula I <CHEM>  wherein R<1> is -H, -OH, -O(C1-C4 alkyl), -OCOC6H5, -OCO(C1-C6 alkyl), or -OSO2(C4-C6 alkyl); R<2> is -H, -OH, -O(C1-C4 alkyl), -OCOC6H5, -OCO(C1-C6 alkyl) or -OSO2(C4-C6 alkyl);     n is 2 or 3; and R<3> is 1-piperidinyl, 1-pyrrolidinyl, methyl-1-pyrrolidinyl, dimethyl-1-pyrrolidinyl, 4-morpholino, dimethylamino, diethylamino, or 1-hexamethyleneimino;  or a pharmaceutically acceptable salt thereof. The compounds are useful for treating diseases such as post-menopausal syndrome, and uterine fibroid disease, endometriosis, and aortal smooth muscle cell proliferation.
Patent NZ-326348-A (NZ)
Title: Method and control circuit for regulation of the operational characteristics especially brightness of gas discharge lamps where lamp current is used as a regulating variable
Inventor: PRIMISSER NORBERT
IPC: H05B41/282
Filed: 1997-01-16
Abstract: PCT No. PCT/EP97/00184 Sec. 371 Date Jul. 14, 1998 Sec. 102(e) Date Jul. 14, 1998 PCT Filed Jan. 16, 1997 PCT Pub. No. WO97/27726 PCT Pub. Date Jul. 31, 1997Gas discharge lamps are for regulated in a manner that is not affected by parasitic capacitances, such as line capacitances, by measuring current which passes through the lamp, calculating an active component of the measured current based on its phase in relation to a reference or by a comparison of the relative phases of the measured current and a voltage applied to the lamp, and regulating the lamp operation based on the active component.
Patent NZ-328252-A (NZ)
Title: Modular components for internal walls
Inventor: LIAO WENCHEN
IPC: E04B2/42
Filed: 1998-09-17
Abstract: A building construction includes a plurality of elongate members 9 interconnectable at their ends with connecting means 1-6 to form a framework 10 of a required size.  At least certain of elongate members 9 including panel connecting means 13 (not shown) along at least part of their length to enable a panel forming part of the building construction, to be secured thereto at a selected position along the length of elongate member 9.  The connecting means engage with the ends of elongate members 9 in a cavity and protrusion relationship.
Patent NZ-336380-A (NZ)
Title: Endothelin antagonists: N-[[2'-[[(4,5-dimethyl-3-isoxazolyl)amino]sulfonyl]-4-(2-oxazolyl)[[1,1'-biphenyl]-2-yl]methyl]-N,3,3-trimethylbutanamide and N-(4,5-dimethyl-3-isoxazolyl)-2'-[(3,3-dimethyl-2-oxo-1-pyrrolidinyl)methyl]-4'-(2-oxazolyl)[1,1'-biphenyl]-2-sulfonamide and salts thereof
Inventor: MURUGESAN NATESAN
IPC: A61P9/04
Filed: 1998-01-26
Abstract: Described are compounds of formula (I) and (II). Formula (I) denotes N-[[2'-[ [(4,5-dimethyl-3-isoxazolyl) amino]sulfonyl]-4-(2-oxazolyl) [1,1'-biphenyl]-2-yl]methyl]-N, 3,3-trimethylbutanamide and Formula (II) denotes N-(4,5-dimethyl-3-isoxazolyl)-2'-[ (3,3-dimethyl-2-oxo-1-pyrrolidinyl) methyl]-4'-(2-oxazolyl) [1,1'-biphenyl]-2-sulfonamide The compounds are useful as endothelin antagonists.
Patent NZ-501569-A (NZ)
Title: Carboxamides useful as 5-HT1F (serotonin receptor) agonists for treating migraine
Inventor: FLAUGH MICHAEL EDWARD
IPC: A61K31/403
Filed: 1998-06-01
Abstract: A carboxamide derivative of the formula shown is useful in the treatment of 5-HT1F receptor agonist related diseases. Wherein; R1 and R2 are independently hydrogen, C1-4alkyl, or -CH2CH2-Aryl where Aryl is phenyl, phenyl monosubstituted with halo, or 1-(C1-6alkyl)pyrazol-4-yl; R3 is C3-6cycloalkyl or a heterocycle; and n is 1 or 2.
Patent NZ-502013-A (NZ)
Title: Land vehicle with adjustable wheel geometry, having one pair of wheel having adjustable track width
Inventor: MARTIN DEREK
IPC: B60B35/12
Filed: 1999-12-22
Abstract: A land vehicle (1) having adjustable wheel geometry, the vehicle having at least one pair of wheels (3,4) arranged on a common virtual axle.  The track width is adjustable whilst the vehicle is in motion between a maximum distance, for stability at low speeds, and position in which the wheels are closely aligned, for high speed cornering.
Patent NZ-503328-A (NZ)
Title: A raisable/lowerable vehicle bed carrying loads
Inventor: KENDALL JEFFREY
IPC: B60P1/02
Filed: 1998-09-16
Abstract: A chassis of the rear portion of a vehicle. The chassis includes a generally horizontal base from which there rearwardly extends a pair of legs. Supported by the legs is a load-receiving bed by means of four hydraulic cylinders. The hydraulic cylinders move the load-receiving bed between a lowered position adjacent to a surface supporting the chassis and a raised transport position. A tailgate is attached to the rear of the load-receiving bed.
Patent NZ-504714-A (NZ)
Title: Road barrier assembly with horizontal rail members maintained in alignment after partial disengagement from post
Inventor: DE MAUSSION JACQUES FREDERIC M
IPC: E04F15/00
Filed: 2000-05-24
Abstract: Bracket 18 consists of fishplate 20 with an attached channel section 22. Bracket 18 interconnects adjacent rails 40,41 to post 14. Disengagement of bracket 18 from post 14 occurs during an impact force while rails 40,41 remain interconnected.
Patent NZ-507642-A (NZ)
Title: Oxidized thymosin beta 4
Inventor: STEVENSON ROBERT DUNCAN
IPC: C12N15/79
Filed: 1999-03-29
Abstract: Use of oxidised thymosin beta 4 in the preparation of pharmaceuticals for the treatment of diseases or conditions associated with an inflammatory response or septic shock.
Patent NZ-513064-A (NZ)
Title: Mono-acyloxy aralkyl or aralkenyl bis quaternary ammonium derivatives of cyclic alkanol diesters useful as neuromuscular relaxants
Inventor: LEE CHINGMUH
IPC: C07D519/00
Filed: 2000-01-31
Abstract: An acyloxy-substituted aralkyl bis-quaternary ammonium derivative of a cyclic alkanol diester has the formula (I) or (II) wherein: R1 and R1' are independently mono-acyloxy substituted aralkyl or aralkenyl; R2 and R2' are independently alkyl, alkenyl or alkynyl; A is optionally substituted alkanedicarbonyl, alkene dicarbonyl, alkynedicarbonyl, cycloalkanedicarbonyl, cycloalkenedicarbonyl, bicycloalkanedicarbonyl, bicycloalkenedicarbonyl, polycycloalkanedicarbonyl, polycycloalkenedicarbonyl or aromatic dicarbonyl; n, m and p are independently 0 to 2; R3 and R3' are independently H or CH3; R4 and R4' are independently H or CH3 or R3 and R4 together form -CH=CH-, -(CH2)h-Y-(CH2)k- or a group of formula (i) or R3' and R4' together form -CH=CH-, -(CH2)h-Y-(CH2)k- or a group of formula (i); Y is CH2, O or S; h and k are independently 0 to 3 and X is a pharmaceutically acceptable anion. The compounds are useful as muscle relaxants.
Patent NZ-515446-A (NZ)
Title: Measurement of magnetic fields using a string fixed at both ends
Inventor: VERYASKIN ALEXEY VLADIMIROVICH
IPC: G01R33/022
Filed: 2000-05-11
Abstract: A method and apparatus is disclosed for detecting magnetic fields in which a string (1) carries an alternating current. The displacement of the string from its unperturbated position due to a magnetic gradient across the string is detected by pick-up coils (L1, L2). The signals from the pick-up coils are demodulated using a signal derived from the alternating current to produce an output.
Patent NZ-517216-A (NZ)
Title: Screening for UDP-glucose: glycoprotein glucosyltransferase (UGGT) activity
Inventor: TESSIER DANIEL C
IPC: C12N1/16
Filed: 2000-07-27
Abstract: Method for determining the effect of a test sample  on UGGT  activity  comprising  the steps  of:  a)  exposing  an acceptor  substrate of UGGT such as acid  phosphatase  to  a labelled  donor  such as UDP-3H-glucose in the  presence  of the  test  sample and UGGT; and b) detecting the  amount  of donor  which  was  transferred  to  the  acceptor  substrate wherein  a  decrease  of donor intake  when  compared  to  a control means that the test sample is a UGGT stimulator  and a  decrease  means that the test sample is a UGGT inhibitor. Also  described is an isolated mammalian cDNA  that  encodes for  rat  UGGT  and to methods of producing  mammalian  UGGT using recombinant vectors.
Patent NZ-519896-A (NZ)
Title: System for channel optimization during point-to-point protocol (PPP) session requests
Inventor: REZAIIFAR RAMIN
IPC: H04W36/12
Filed: 2001-01-26
Abstract: A method of optimizing radio access network packet data service node interface communications channel resources in a communications network when a mobile station moves from a first infrastructure element to a second infrastructure element associated with a packet data services node of the communications network, comprises the step of transmitting from the second infrastructure element a message including a number of dormant network connections associated with the mobile station and a reduced list of identifiers associated with the dormant network connections. A method of simplifying Packet Control Function network element functionality when a mobile station moves from a first infrastructure element of the packet data services network to a second infrastructure element of the packet data services network comprises the step of maintaining a reduced entry PPP connection table. A method of optimizing the Air Interface traffic channel resources in a communications network when the mobile station moves from a first infrastructure element of the packet data services network to a second infrastructure element of the packet data services network, comprises the step of transmitting from the mobile station a message including a number of dormant network connections associated with the mobile station and enhanced information associated with the dormant network connections.
Patent NZ-522410-A (NZ)
Title: Substituted 1-aminoalkyl-lactams and their use as muscarinic receptor antagonists
Inventor: MADERA ANN MARIE
IPC: C07D223/10
Filed: 2001-05-17
Abstract: Compounds which are muscarinic M2/M3 receptor antagonists of Formula I, where: - R1 and R2 are independently in each occurrence hydrogen, halogen,(C1-6)-alkyl, -OR',-SR',-NR'R",-SOR',-S02R',-COOR',-OCOR',-OCONR'R", -OSO2R',-OSO2NR'R";-NR'SO2R",-NR'COR",-SO2 NR'R", -S02(CH2)1-3CONR'R", -CONR'R", cyano, halogenalkyl or nitro; or - R' and R" are independently in each occurrence hydrogen, (C1-6)-alkyl, substituted(C1-6)-alkyl, aryl, heterocyclyl, heteroaryl, aryl-(C1-3)-alkyl, heteroaryl-(C1-3alkyl, heterocyclyl-(C1-3)-alkyl, cycloalkyl-alkyl, cycloalkyl, or R' and R" together with the nitrogen they are attached may also form a 5-to 7-membered ring, optionally incorporating one additional ring heteroatom chosen from N,O or S (O)0-2; - R3 independently in each occurrence (C1-6)-alkyl, (C1-6)-alkenyl, (C1-6)-alkynyl or cycloalkyl ; or - One of X, Y or Z is independently -S-, -O-, or > N-R4, the others are -CH2- ; - R4 is hydrogen, (C1-6)-alkyl, halogenalkyl, aryl-(C1-6)-alkyl, heteroaryl(1-6)-alkyl, -(C1-6)-CR'R'R', -COOR', -SO2R', -C(O)R', -SO2(CH2)0-3NR'R", -CONR'R", or -PO(OR')2, - where R' and R" are as defined above; - p is an integer from 1 to 3 inclusive; - m is an integer from 0 to 3 inclusive; - n is an integer from 1 to 6 inclusive. These compounds are useful for treating diseases associated with smooth muscle disorders associated with genitourinary or gastrointestinal or respiratory tract.
Patent NZ-524878-A (NZ)
Title: Non-redirective gating crash cushion apparatus for movable, permanent and portable roadway barriers
Inventor: DUCKETT JOHN W
IPC: E01F15/08
Filed: 2001-10-03
Abstract: The crash cushion apparatus includes a nose piece assembly (11), one or more impact absorption elements (12), and a transition/attachment assembly (14). The impact absorption elements (12) are composed of a plastic container having a forward end, a rearward end, and two sides. Each side has at least one vertical indentation (20); one side bearing a first number of vertical indentations and the other side bearing at least one more vertical indentation than the first side. When a plurality of impact absorption elements are assembled, the elements should be so arranged, that adjacent elements alternate the number of vertical indentations (20) on their respective sides.
Patent NZ-528462-A (NZ)
Title: Compositions and methods useful for HCV infection
Inventor: KWONG ANN
IPC: C12N7/00
Filed: 2002-03-27
Abstract: The present disclosure provides compositions comprising cells that can effectively produce HCV after HCV infection, compositions for culturing the cells, methods for making the composition and methods for injecting the cells in the composition with HCV. The present disclosure also provides methods for assaying HCV production and methods for evaluating compounds that affect the production of HCV.
Patent NZ-534399-A (NZ)
Title: Monoclonal antibodies against extracellular loops of C5aR
Inventor: MACKAY CHARLES REAY
IPC: A61K39/395
Filed: 2003-01-24
Abstract: Disclosed is an antibody that is reactive with an extracellular loop(s) of C5aR other than the N-terminal domain and which reduces or inhibits the binding of C5a to C5aR, with the proviso that the antibody reduces binding of C5a to C5aR by at least 20% when compared with the binding of C5a to C5aR in the absence of the antibody.
Patent NZ-536382-A (NZ)
Title: Use of substituted isoxazoles for the production of a medicament for treating inflammation
Inventor: ROGERS ROLAND S
IPC: C07D413/04
Filed: 1996-02-12
Abstract: The use of a therapeutically effective amount of a compound of Formula I, II, III, IV or IV for the production of a medicament for treating inflammation or an inflammation-associated disorder.
Patent NZ-537182-A (NZ)
Title: Diazabicyclononane and -decane derivatives and their use as opioid receptor ligands
Inventor: PETERS DAN
IPC: A61P1/08
Filed: 2003-07-24
Abstract: Disclosed are compounds of formula (I), wherein: Q is -CH2-CH2- or -CH2-CH2-CH2-, one of R1 and R2 is -CH2-CH2-CH2-R3, -CH2-CH=CH-R3, or -CH2-CC-R3, R3 is optionally substituted aryl or heteroaryl, the other of R1 and R2 is -CO-R4, and R4 is alkyl, cycloalkyl, cycloalkylalkyl, aryl or arylalkyl, The compounds are used for the manufacture of medicaments for the treatment of conditions responsive to modulation of the opioid receptor.
Patent NZ-537277-A (NZ)
Title: Recombinant production of mixtures of antibodies
Inventor: VAN BERKEL PATRICK HENRIKUS CO
IPC: C07K16/00
Filed: 2003-07-15
Abstract: Disclosed is a method for producing mixtures of antibodies in a recombinant host cell. A nucleic acid sequence encoding a light chain and nucleic acid sequences encoding different heavy chains are expressed in a recombinant host cell. The antibodies in the mixtures comprise identical light chains paired to different heavy chains capable of pairing to the light chain, thereby forming functional antigen binding domains. Mixtures of antibodies are also provided.
Patent NZ-537870-A (NZ)
Title: New effector conjugates, process for their production and their pharmaceutical use
Inventor: BERGER MARKUS
IPC: A61K47/48
Filed: 2003-07-31
Abstract: Conjugates of epothilones and epothilone derivatives (as effectors) with suitable biomolecules (as recognition units) are disclosed. Their production is carried out by the effectors being reacted with suitable linkers, and the compounds that are produced are conjugated to the recognition units. The pharmaceutical use of the conjugates for treating proliferative or angiogenesis-associated processes is described.
Patent NZ-541467-A (NZ)
Title: Punch tool for tissue sampling
Inventor: HOWELL TODD MICHAEL
Filed: 2005-07-25
Abstract: A sampling means for obtaining an organic sample (85) from an animal. The sampling means includes a punch means (18) adapted to be securable in use with a first part (70) of an applicator (100). A housing means (8) is adapted in use to be accommodated, or provided, by a second part (2) of the applicator (100). Operation of the applicator (100) in use being adapted to move said punch means (18) through a required part (80) of an animal to extract a sample (85) thereof. The punch means (18) being receivable within said housing means (8) to enable said housing means (8), with said punch means (18) and said sample (85), to be removable from said second part (2) of said applicator (100), and wherein the sampling means is not associated with an animal tag.
Patent NZ-547265-A (NZ)
Title: Therapeutic foam
Inventor: WRIGHT DAVID DAKIN IORWERTH
IPC: A61K9/12
Filed: 2004-11-17
Abstract: Disclosed is a foam comprising a liquid phase and a gas phase wherein the liquid phase comprises at least one sclerosing agent and the gas phase consists of at least one physiologically acceptable gas, physiologically acceptable gases being oxygen, carbon dioxide, nitrous oxide and helium, wherein gaseous nitrogen is present in the gas phase in an amount ranging from 0.0001 percent to 0.8 percent by volume. Also disclosed is a canister, the contents of which comprise said foam and the use of said foam for the manufacture of a medicament for phlebologic treatment.
Patent NZ-552268-A (NZ)
Title: Automated pallet inspection and repair
Inventor: LUCAS MICHAEL DAVID
Filed: 2003-12-10
Abstract: An automatic pallet inspection cell 10 comprises one or two multi axis robot arms 14, 15 which terminate in either internal or exterior pallet grippers. The robots are used to transport a gripped pallet 12 through an automated inspection station 16 which compiles a three dimensional data map of a pallet surface. A processor interprets the map and produces a recipe for the robot(s). One or more stations 17, 18, 19 conduct pallet repair operations that are specified by the recipe. A method for levelling a pallet prior to board removal by a band saw 17 is also disclosed, characterised by rolling the pallet relative to a blade of the band saw to a first and second roll angle, and positioning the pallet at a position which is an average of the first and second roll angles. This application is directed to the above method for levelling the pallet by such averaging.
Patent NZ-552435-A (NZ)
Title: Drug delivery apparatus comprising an automated response monitoring system
Inventor: MARTIN JAMES F
IPC: A61B5/04
Filed: 2005-06-09
Abstract: A sedation drug delivery apparatus and more particularly, a closed loop sedation drug delivery apparatus is disclosed. The apparatus comprises an automated response monitoring system (ARM), an index of depth of anesthesia monitoring apparatus and a sedation drug infusion device. An index of depth of anesthesia set point is determined by an index of depth of anesthesia value that coincides with a level of anesthesia where the patient fails to respond to ARM. The infusion device administers the drug to the patient while the index the index of depth of anesthesia monitoring device monitors the patient's index of depth of anesthesia values relative to the set point.
Patent NZ-555352-A (NZ)
Title: 12-aryl prostaglandin analogs
Inventor: DONDE YARIV
IPC: A61K31/5575
Filed: 2005-12-08
Abstract: Disclosed are aryl prostagland derivatives of formula (I) or a pharmaceutically acceptable salt or an amine or ester prodrug thereof, wherein a dashed line represents the presence or absence of a covalent bond; Y is a carboxylic acid, sulphonic acid, or phosphonic acid; or an amide or ester thereof comprising from 0 to 12 carbon atoms; or Y is a hydroxymethyl, or a tetrazolyl functional group; A is -(CH2)6-, cis -CH2CH=CH-(CH2)3-, or -CH2Ca"C-(CH2)3-, wherein 1 or 2 carbon atoms may be substituted with S or O; or A is -(CH2)m-Ar-(CH2)o- wherein Ar is substituted or unsubstituted phenyl or monocyclic heteroaryl, the sum of m and o is from 1 to 4, and wherein one CH2 may be substituted with S or O; X is C=O, CHF, CF2, CHCl, or CHOH; wherein if X is CHOH, then OH is in the b-configuration; R is a hydrocarbyl or a hydroxyhydrocarbyl moiety comprising from 1 to 12 carbon atoms; D is independently selected from CO2H and salts thereof, alkoxy, alkyl, cyclic and unsaturated hydrocarbyls, carboxylic acid esters, CN, NO2, CF3, F, Cl, Br, I, sulfonyl esters, SO3H and salts thereof wherein D comprises from 1 to 6 non-hydrogen atoms; and n is an integer from 0 to 4, provided that when X is C=O, Y is not an amide of a carboxylic acid. Also disclosed is the use of a compound as defined above for the manufacture of a medicament for the treatment of glaucoma or the reduction of intraocular pressure.
Patent NZ-565720-A (NZ)
Title: Aerodynamic vehicle aid
Inventor: STEEL KENNETH
IPC: B62D35/00
Filed: 2008-03-30
Abstract: Apparatus for enhancing the aerodynamics of vehicles, particularly cargo haulage vehicles such as trucks and trains, are disclosed. An aerodynamic aid (12) is located at the leading edge (13) of part of a vehicle, such as the top edge of a bluff body trailer (2). The aid includes; a first aerofoil (14) with an arcuate portion (15) projecting forwardly from the vehicle, with upper (16) and lower (17) regions extending from the arcuate portion to the vehicle body; and a second aerofoil (18) oriented parallel to, above, and trailing the arcuate portion of the first aerofoil. At least a portion of the airflow generated by forward movement of the vehicle is diverted between the two aerofoils.